Skip to main content
OpenTrials
Completed

NCT Number: NCT03657355

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Altasciences Company Inc., Montreal, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent prior to any study-mandated procedure
  • Male or female healthy subjects, 18-55 years of age (inclusive) at Screening
  • Body mass index of 18.0-33.0 kg/m2 (inclusive) at Screening and a minimum weight of 50.0 kg at Screening
  • Current sedative users who have used sedatives (e.g., benzodiazepines, zolpidem, eszopiclone, gamma-hydroxybutyrate, barbiturates) for recreational (non-therapeutic) purposes (i.e., for psychoactive effects) at least ten times in their life and at least once in the 12 weeks before Screening
  • Women of childbearing potential must consistently and correctly use a reliable method of contraception with a failure rate of < 1% per year, be sexually inactive, or have a vasectomized partner
  • Women of non-childbearing potential
  • Male subjects are required to use a medically acceptable method of contraception throughout the entire study period and for at least 90 days after last study drug administration

Exclusion criteria

  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s)
  • Positive HIV or hepatitis B/C test at Screening
  • Female subjects who are currently pregnant or lactating or who are planning to become pregnant within 1 month of the last study treatment administration
  • Modified Swiss Narcolepsy Scale total score < 0 at Screening or history of narcolepsy or cataplexy
  • Substance or alcohol dependence within 2 years prior to Screening or prior participation in a substance or alcohol dependence rehabilitation program
  • Subjects who have a positive urine drug screen at admittance to the qualification or core phase
  • Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep disorders, restless legs syndrome (RLS), nightmare disorder, non-rapid eye movement (REM), sleep arousal disorders, REM sleep behavior disorder, circadian rhythm sleep-wake disorders, or narcolepsy
  • Any of the following SLEEP-50 Questionnaire scores at Screening:
  • ≥ 15 on Apnea subscale;
  • ≥ 7 on Narcolepsy subscale;
  • ≥ 7 on RLS or Periodic limb movement disorder subscale;
  • ≥ 8 on Circadian Rhythm subscale;
  • ≥ 7 on Sleepwalking subscale;
  • ≥ 3 on Item 32 and ≥ 9 on Items 33 to 35 (i.e., on nightmare subscale);
  • ≥ 15 on Impact subscale.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Treatment and study plan

ACT-541468

Drug

ACT-541468 will be administered as 50 mg tablets for oral use.

Suvorexant

Drug

Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.

zolpidem

Drug

Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.

Placebo

Drug

Matching-placebo will be used.

Primary outcomes

  1. Maximum effect (Emax) of the Drug Liking VAS ('at this moment') over 24 h post-dose during each treatment period

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

Secondary outcomes

  1. Drug Liking VAS (bipolar)

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

  2. Overall Drug Liking VAS (bipolar)

    Time frame: Duration: for up to 12 hours post-dose

    VAS = visual analogue scale

  3. Take Drug Again VAS (bipolar)

    Time frame: Duration: for up to 12 hours post-dose

  4. Good Effects VAS (unipolar)

    Time frame: Duration: for up to 24 hours post-dose

  5. Drug Similarity VAS

    Time frame: Duration: for up to 1 hour post-dose

    VAS = visual analogue scale

  6. Bad Effects VAS (unipolar)

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

  7. Alertness/Drowsiness VAS (bipolar)

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

  8. Any Effects VAS (unipolar)

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

  9. Feeling High VAS (unipolar)

    Time frame: Duration: for up to 24 hours post-dose

    VAS = visual analogue scale

  10. Bowdle VAS Internal and External Perceptions

    Time frame: Duration: for up to 24 hours post-dose

  11. Observer's Assessment of Alertness/Sedation composite and sum scores

    Time frame: Duration: for up to 24 hours post-dose

  12. Reaction time task score

    Time frame: Duration: for up to 8 hours post-dose

  13. Rapid visual information processing score

    Time frame: Duration: for up to 8 hours post-dose

  14. Paired Associates Learning score

    Time frame: Duration: for up to 8 hours post-dose

Other outcomes

  1. AUC(0-t) of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  2. AUC(0-∞) of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  3. Cmax of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  4. tmax of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  5. t½ of ACT-541468

    Time frame: Duration: for up to 24 hours post-dose

  6. Treatment-emergent adverse events (AEs)

    Time frame: All AEs from (first) admittance on Day -1 up to EOS, i.e. for up to 9 weeks

  7. Treatment-emergent serious AEs (SAEs)

    Time frame: SAE reporting: from signature of informed consent up to EOS, i.e. for up to 13 weeks

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 5, 2018
Registry last updated
Sep 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.